Sugi Predict

Sugi Predict / Compounds / SCHEMBL3484433

SCHEMBL3484433

SCHEMBL3484433

COc1ccc(CN(Cc2ccc(OC)cc2)C(=O)O)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 3/20 0.60
▸ TSHR P16473 3/20 0.59
▸ USP2 O75604 1/20 0.59
▸ ALDH1A1 P00352 3/20 0.58
▸ NPSR1 Q6W5P4 2/20 0.58
▸ HTT P42858 3/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ ACHE P22303 1/20 0.57
▸ LDHA P00338 1/20 0.56
▸ APLNR P35414 1/20 0.55
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ ALOX12 P18054 1/20 0.54
▸ GPR55 Q9Y2T6 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ ALOX5 P09917 1/20 0.53
▸ TAS2R14 Q9NYV8 1/20 0.53
▸ LPAR1 Q92633 1/20 0.52
▸ LPAR5 Q9H1C0 1/20 0.52
▸ MAPT P10636 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3614141 0.88 TDP1 (0.54) TDP1TSHRUSP2ALDH1A1NPSR1
SCHEMBL20472128 0.88 TDP1 (0.54) TDP1TSHRUSP2ALDH1A1NPSR1
SCHEMBL9416611 0.86 TSPO (0.58) TDP1TSHRUSP2ALDH1A1NPSR1
SCHEMBL11806780 0.86 ALDH1A1 (0.56) TDP1TSHRUSP2ALDH1A1NPSR1
SCHEMBL17801922 0.86 TSHR (0.55) TDP1TSHRUSP2ALDH1A1NPSR1
SCHEMBL18646559 0.86 TSHR (0.62) TDP1TSHRUSP2ALDH1A1NPSR1
SCHEMBL20472046 0.85 ALDH1A1 (0.52) TDP1TSHRUSP2ALDH1A1NPSR1
SCHEMBL25426321 0.85 ALDH1A1 (0.58) TDP1TSHRUSP2ALDH1A1NPSR1
SCHEMBL10458603 0.85 ALDH1A1 (0.55) TDP1TSHRUSP2ALDH1A1NPSR1
SCHEMBL6122171 0.85 ALDH1A1 (0.58) TDP1TSHRUSP2ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12636274-B2 Pharmaceutical compositions and methods for systemic treatment of solid tumors 7 HILLS PHARMA INC. (US) 2026-05-26 — — US claimed
US-12201686-B2 Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound 7 HILLS PHARMA INC. (US) 2025-01-21 — — US claimed
CN-117980302-A Piperazine-based agonists of LFA-1 and VLA-4 德克萨斯心脏研究所 2024-05-03 — — CN claimed
US-11484524-B2 Compositions and methods to improve adoptive cell therapies 7 Hills Pharma LLC (US) 2022-11-01 — — US claimed
US-11311619-B2 Integrin activator vaccine compositions 7 Hills Pharma Inc. and Texas Heart Institute (US) 2022-04-26 — — US claimed
EP-2640721-B1 AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS TEXAS HEART INST (US) 2018-06-06 — — EP claimed
US-12109263-B2 Integrin agonists or activating compounds and methods for making and using same 7 HILLS PHARMA INC. 2024-10-08 — — US disclosed
CN-117980302-A Piperazine-based agonists of LFA-1 and VLA-4 德克萨斯心脏研究所 2024-05-03 — — CN disclosed
US-20220118086-A1 INTEGRIN AGONISTS OR ACTIVATING COMPOUNDS AND METHODS FOR MAKING AND USING SAME 7 Hills Pharma LLC (US) 2022-04-21 — — US disclosed
EP-3104867-A1 COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS 7 HILLS INTERESTS, LLC (US) 2016-12-21 — — EP disclosed
WO-2015123447-A1 COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS 7 HILLS PHARMA, LLC (US) 2015-08-20 — — WO disclosed
EP-2049200-B1 NOVEL INHIBITORS OF BETA-LACTAMASE METHYLGENE INC (CA) 2015-04-29 — — EP disclosed
US-8440643-B2 Inhibitors of beta-lactamase METHYLGENE INC. (CA) 2013-05-14 — — US disclosed
US-20100279983-A1 NOVEL INHIBITORS OF BETA-LACTAMASE METHYLGENE INC. 2010-11-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11311619-B2 Integrin activator vaccine compositions ITGAM, ITGA2B, ITGA1 TDP1 4410/4885TSHR 1793/4885USP2 3773/4885
US-11484524-B2 Compositions and methods to improve adoptive cell therapies ITGB7, ITGB1, ITGA1 TDP1 4383/4885TSHR 943/4885USP2 4536/4885
US-12636274-B2 Pharmaceutical compositions and methods for systemic treatment of solid tumors CD4, VCAM1, ITGA1 TDP1 4811/4885TSHR 1112/4885USP2 1490/4885
US-20220118086-A1 INTEGRIN AGONISTS OR ACTIVATING COMPOUNDS AND METHODS FOR MAKING AND USING SAME ICOS, CD47, CD274 TDP1 3886/4885TSHR 708/4885USP2 4351/4885
US-12201686-B2 Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound CD47, CD274, ITGB1 TDP1 4360/4885TSHR 2082/4885USP2 3845/4885
US-20100279983-A1 NOVEL INHIBITORS OF BETA-LACTAMASE MGAM, MGAM2, PGLS TDP1 3764/4885TSHR 4294/4885USP2 1791/4885
US-12109263-B2 Integrin agonists or activating compounds and methods for making and using same ICOS, CD47, CD274 TDP1 3886/4885TSHR 708/4885USP2 4351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.